Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electromagnetic Fields and Regorafenib in Advanced Hepatocellular Carcinoma
NCT04327700Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2021
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Progression-Free Survival at 12 weeks. Started Jan 2021; status: terminated.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04327700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327700.